Vitamins and mineralsStudies updated this monthVitamin C and cancer — why does this topic still divide doctors?
What do Natural Therapy Specialists write?
In the study described, a fasting-mimicking diet and vitamin C reduced the growth of cancer cells in mice, and combining the two had a strong effect.
Nine people with advanced pancreatic cancer were given intravenous vitamin C along with chemotherapy, and the disease did not progress for six months after treatment.
Jerzy Zięba believes that oral administration involves too low a dose for the results to be convincing, and stresses the importance of the form and method of administration.
Andrzej Frydrychowski claims that giving high doses of vitamin C intravenously is prohibited and may lead to disciplinary proceedings before medical chambers.
Andrzej Frydrychowski believes that scientific arguments do not persuade those who handle such cases, and links the restrictions to a ban on inexpensive treatment.
Hubert Czerniak presents deficiencies in vitamins C and D as a cause of weakened collagen structures.
What does scientific research from PubMed · Europe PMC say?
We selected 8 studies with the best, positive results. This is a selection, not a full review of all research.
Total number of studies on this topic in PubMed: 7 393.
Aim of the study: Intravenous vitamin C (IVC) is a controversial complementary cancer therapy, widely used in naturopathic and integrative oncology settings. We conducted a systematic review of human interventional and observational studies assessing IVC use in cancer patients.
Results: Of 897 records, a total of 39 reports from 37 studies were included: 2 randomized controlled trials (RCTs), 15 uncontrolled trials, 6 observational studies, and 14 case reports. IVC doses ranged from 1 g to more than 200 g of ascorbic acid per infusion, typically given 2 to 3 times a week. IVC does not appear to increase toxicity or interfere with the antitumor effects of gemcitabine/erlotinib therapy or paclitaxel and carboplatin. Based on 1 RCT and data from uncontrolled human trials, IVC may improve time to relapse and possibly help reduce tumor mass and improve survival when combined with chemotherapy. IVC may improve quality of life, physical function, and chemotherapy-related side effects, including fatigue, nausea, insomnia, constipation, and depression. Case reports document several instances of tumor regression and long-term survival without disease associated with IVC use. There is limited high-quality clinical evidence on the safety and effectiveness of IVC.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: The association between dietary vitamin C intake and breast cancer survival is inconsistent, and few studies have specifically examined vitamin C supplement use among women with breast cancer. The purpose of this study was to summarize results from prospective studies on the association between vitamin C supplement use and dietary vitamin C intake and breast cancer-specific and overall mortality.
Results: The ten identified studies examined vitamin C supplement use (n=6) and dietary vitamin C intake (n=7) and included 17,696 breast cancer cases, 2791 total deaths, and 1558 breast cancer-specific deaths. The summary RR (95% CI) for vitamin C supplement use after diagnosis was 0.81 (95% CI 0.72-0.91) for overall mortality and 0.85 (95% CI 0.74-0.99) for breast cancer-specific mortality. The summary RR for a 100mg per day increase in dietary vitamin C intake was 0.73 (95% CI 0.59-0.89) for overall mortality and 0.78 (95% CI 0.64-0.94) for breast cancer-specific mortality. The results of this meta-analysis suggest that vitamin C supplement use after diagnosis may be associated with a reduced risk of mortality. Dietary vitamin C intake was also statistically significantly associated with a reduced risk of overall and breast cancer-specific mortality.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Skin cancer is the most common cancer in the United States and among Caucasians worldwide, with more people diagnosed each year than with all other cancers combined. Basal cell cancer is the most common form, with an estimated 4.3 million cases diagnosed annually and treatment costs estimated at $4.8 billion.
Results: After 8 weeks, post-treatment biopsies showed complete resolution of 13/15 (86.7%) lesions in the ascorbic acid group, while 8/14 (57.1%) lesions in the IMQ group had resolved (p < 0.05 Chi Square). Topical ascorbic acid was superior at 8 weeks and non-inferior at 12 weeks to topical imiquimod for treating low-risk nodular and superficial lesions. In addition, ascorbic acid was associated with fewer adverse effects than imiquimod. At the 30mo follow-up, 70% of patients in the imiquimod group showed residual hypopigmentation, compared with 0% in the ascorbate group.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: More than half of human colorectal cancers (CRCs) have either KRAS or BRAF mutations and are often resistant to approved targeted therapies. We found that cultured human CRC cells with KRAS or BRAF mutations are selectively killed when exposed to high levels of vitamin C.
Results: As a result, reactive oxygen species accumulate and inactivate glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Inhibition of GAPDH in highly glycolytic KRAS- or BRAF-mutant cells leads to an energy crisis and cell death, which is not seen in KRAS- and BRAF-wild-type cells. High-dose vitamin C impairs tumor growth in Apc/Kras(G12D) mutant mice. These results provide a mechanistic rationale for exploring the therapeutic use of vitamin C for CRCs with KRAS or BRAF mutations.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Vitamin C is an antioxidant with a potential role in preventing digestive system cancers, but there is still no consensus on whether vitamin C plays a causal role in these cancers. The aim of this study was to use Mendelian randomization to investigate potential causal associations between vitamin C and the risk of digestive system cancers.
Results: Genetically predicted higher circulating vitamin C showed a suggestive association with lower risk of small intestine and colorectal cancer after accounting for multiple testing. The odds ratio per 1 standard deviation increase in circulating vitamin C was 0.55 (95% confidence interval 0.32-0.94; P = 0.029) for small intestine cancer and 0.84 (95% confidence interval 0.73-0.96; P = 0.013) for colorectal cancer. There was a suggestive association between genetically predicted higher circulating vitamin C and lower risk of liver cancer in FinnGen, but no association in the meta-analysis (odds ratio 0.69; 95% CI 0.36-1.32; P = 0.265). Genetically predicted circulating vitamin C was not associated with cancers of the esophagus, stomach, or pancreas. This Mendelian randomization study indicates that vitamin C might play a role in preventing small intestine and colorectal cancer.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Growing evidence indicates that vitamin C may be a powerful anticancer agent when given intravenously and in high doses (high-dose IVC). Early-phase clinical trials have confirmed the safety of IVC and indicated that it may be effective in eliminating tumor cells in various types of cancer.
Results: Therefore, there is a need for greater awareness of the use of this highly promising, non-toxic cancer treatment in clinical settings. In this review, we provide a detailed overview of preclinical and clinical studies using high-dose IVC as an anticancer agent, as well as a detailed assessment of the main known molecular mechanisms involved. We place special focus on global molecular profiling studies in this area. In addition, we discuss the future implications of high-dose vitamin C in cancer treatment and make recommendations for further research.
“Not stated” does not mean nobody paid — the database does not always record it.
Aim of the study: Evidence on antioxidant vitamin intake and esophageal cancer risk in Asian populations remains limited. Given sex differences in incidence and major risk factors, we examined sex-specific associations in a large Japanese cohort.
Results: During a median 15.6-year follow-up, 497 participants (447 men and 50 women) developed esophageal cancer, including 424 cases of squamous cell carcinoma. Among men, higher vitamin C intake was associated with lower risk (HR for the highest-versus-lowest quartile, 0.62; 95% CI, 0.46-0.85; P for trend = 0.036). Among women, the corresponding HR was 0.71 (95% CI, 0.31-1.63; P for trend = 0.465). Among male never-smokers, an inverse association was observed (HR, 0.35; 95% CI, 0.14-0.70; P for trend = 0.032), whereas no clear association was found among male ever-smokers. Other antioxidant vitamins showed no clear associations. Higher dietary vitamin C intake was associated with lower esophageal cancer risk among men, particularly never-smokers. The limited number of cases did not allow a clear interpretation for women.
“Not stated” does not mean nobody paid — the database does not always record it.
“Not stated” does not mean nobody paid — the database does not always record it.
What do orthomolecular medicine doctors write?
Sources (14)
- Jerzy Zięba — Przegląd doniesień na temat witaminy C Jerzy Zięba
- Andrzej Frydrychowski — Witamina C w postaci liposomalnej
- Hubert Czerniak — Powstrzymać raka
- Intravenous Vitamin C and Cancer: A Systematic Review. · Integr Cancer Ther 2014
- Vitamin C and survival among women with breast cancer: a meta-analysis. · Eur J Cancer 2014
- Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma. · Biomed Pharmacother 2022
- Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. · Science 2015
- Circulating vitamin C and digestive system cancers: Mendelian randomization study. · Clin Nutr 2022
- High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. · J Exp Clin Cancer Res 2021
- Dietary antioxidant vitamins and risk of esophageal cancer: The Japan Public Health Center-based prospective study. · J Epidemiol 2026
- Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP. · Blood Cancer Discov 2026
- Orthomolecular Medicine News Service — Vitamin C Slows Cancer Down
- Orthomolecular Medicine News Service — High Dose Vitamin C for Cancer - The Struggle with "Non-Evidence-Based" Medical Practice
- Orthomolecular Medicine News Service — VITAMIN A: Cancer Cure or Cancer Cause?
Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.